← All news
Milestone
HemaSense Shares first Preclinical Animal Data at TCT 2025
Nathan Friedman, CEO, shared the results of the first preclinical animal study of the HemaSense Device on the Innovation stage at TCT 2025.
The HemaSense device was placed on 3 animals in a porcine model and used to monitor a controlled bleed in the femoral region. See presentation archives at the TCT website or contact HemaSense for more details.
HemaSense is an investigational device and is not yet approved by the FDA. Claims have not been reviewed by the FDA.